Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Merck Sharp & Dohme LLC
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche
M.D. Anderson Cancer Center
Eikon Therapeutics
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Centre Francois Baclesse
Sanofi
AstraZeneca
GlaxoSmithKline
Genentech, Inc.
iTeos Therapeutics
Icahn School of Medicine at Mount Sinai
Fondazione del Piemonte per l'Oncologia
National Cancer Institute (NCI)
Shanghai Henlius Biotech
Shanghai Henlius Biotech
Eastern Cooperative Oncology Group
University of Kentucky
University of Kentucky
Hoffmann-La Roche
Noxopharm Limited
Genentech, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Bristol-Myers Squibb
University of Cincinnati
Takeda
Merck Sharp & Dohme LLC
GlaxoSmithKline
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
ChineseAMS
Accenture
GlaxoSmithKline
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Hoffmann-La Roche
Achieve Life Sciences
Ohio State University Comprehensive Cancer Center
Merrimack Pharmaceuticals
SCRI Development Innovations, LLC
Sanofi
Dana-Farber Cancer Institute
Tesaro, Inc.
Oncolytics Biotech